A new method to quantify β-antithrombin glycoform in plasma reveals increased levels during the acute stroke event

β-antithrombin, the minor antithrombin glycoform in plasma, is probably the major thrombin inhibitor in vivo because of its high heparin affinity. The levels and variability of this glycoform in general population and its relevance in thromboembolic diseases is unknown since there is no specific method to measure this glycoform in clinical samples.

Source: Thrombosis Research - July 6, 2015 Category: Hematology Authors: M.E. de la Morena-Barrio, A. García, I. Martínez-Martínez, A. Miñano, J. Padilla, J. Navarro-Fernández, V. Roldán, S. Águila, J.A. Iniesta, J. Corral, V. Vicente Source Type: research